A5061623935- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Sexual function and dysfunction studies
- Urinary Bladder and Prostate Research
- Urological Disorders and Treatments
- Hormonal and reproductive studies
- Urologic and reproductive health conditions
- Renal and related cancers
- Multiple and Secondary Primary Cancers
- Renal and Vascular Pathologies
- Genital Health and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Pelvic floor disorders treatments
- Sexual Differentiation and Disorders
- Cancer Immunotherapy and Biomarkers
- Sexuality, Behavior, and Technology
- Sperm and Testicular Function
- Cancer, Lipids, and Metabolism
- Pediatric Urology and Nephrology Studies
- Colorectal Cancer Surgical Treatments
- Cardiac, Anesthesia and Surgical Outcomes
IRCCS Ospedale San Raffaele
2016-2025
Vita-Salute San Raffaele University
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2016-2025
Ospedale Antonio Cardarelli
2025
Institute of Experimental Endocrinology of the Slovak Academy of Sciences
2015-2024
San Raffaele University of Rome
2015-2024
University College London
2024
Fondazione IRCCS Istituto Nazionale dei Tumori
2020-2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2024
We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased for disease.
Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) which standard cisplatin-based chemotherapy is poorly used. Patients and Methods In PURE-01 study, patients had a predominant urothelial histology clinical (c)T≤3bN0 stage tumor. They received three cycles 200 mg every 3 weeks RC. The primary end point in intention-to-treat population was pathologic complete response (pT0). Biomarker...
Abstract BACKGROUND There is few data on what constitutes the distribution of metastatic sites in prostate cancer (PCa). The aim our study was to systematically describe most common metastases a contemporary cohort PCa patients. METHODS Patients with were abstracted from Nationwide Inpatient Sample (1998–2010). Most within entire population described. Stratification performed according presence single or multiple (≥2 sites) metastases. Additionally, we evaluated amongst patients and without...
No AccessJournal of UrologyVoiding Dysfunction1 May 2008Holmium Laser Enucleation Versus Transurethral Resection the Prostate: Results From a 2-Center Prospective Randomized Trial in Patients With Obstructive Benign Prostatic Hyperplasiais accompanied byHOLMIUM LASER ENUCLEATION VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE: RESULTS FROM A 2-CENTER, PROSPECTIVE, RANDOMIZED TRIAL IN PATIENTS WITH OBSTRUCTIVE BENIGN PROSTATIC HYPERPLASIA Francesco Montorsi, Richard Naspro, Andrea Salonia,...